Treatment of Primary Coronary Artery Vascular Lesions With Biolimus Coated Coronary Balloon Dilation Catheter - Trial NCT06385067
Access comprehensive clinical trial information for NCT06385067 through Pure Global AI's free database. This phase not specified trial is sponsored by JW Medical Systems Ltd and is currently Not yet recruiting. The study focuses on Coronary Artery Disease. Target enrollment is 400 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
JW Medical Systems Ltd
Timeline & Enrollment
N/A
May 10, 2024
Dec 30, 2026
Primary Outcome
Target lesion failure rate (TLF)
Summary
The purpose of the study was to further evaluate the long-term safety and efficacy of the
 Biolimus Coated Coronary Artery Balloon Dilation Catheter in the real world.
 
 The study population was patients with primary coronary vascular lesions with a blood vessel
 diameter of 2.0mm-2.75mm.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06385067
Device Trial